Skip to main content

Table 1 Clinicopathological features of 50 cases biopsied/resected to recurrence

From: The effect of smoking on biological change of recurrent breast cancer

ParametersNumber of patients (n = 50) (%)
Age at operation (years old)60 (37–79)
Tumor size (mm)21.8 (8.0–45.0)
Lymph node metastasis
 N0/N1/N243 (86.0%)/5 (10.0%)/2 (4.0%)
Estrogen receptor (ER) of primary tumor
 Negative/positive13 (26.0%)/37 (74.0%)
Progesterone receptor (PgR) of primary tumor
 Negative/positive15 (30.0%)/35 (70.0%)
HER2 of primary tumor
 Negative/positive48 (96.0%)/2 (4.0%)
Ki67 of primary tumor
 ≤14%/> 14%19 (38.0%)/31 (62.0%)
Intrinsic subtype
 HRBC/HER2BC/TNBC38 (76.0%)/2 (4.0%)/10 (20.0%)
Chemotherapy after surgery
 No/yes37 (74.0%)/13 (26.0%)
Endocrine therapy after surgery
 No/yes14 (28.0%)/36 (72.0%)
Radiation therapy after surgery
 No/yes39 (78.0%)/11 (22.0%)
Trastuzumab after surgery
 No/yes49 (98.0%)/1 (2.0%)
No-treatment after surgery
 No/yes44 (88.0%)/6 (12.0%)
Age at recurrence (years old)62 (41–86)
Recurrent tumor site biopsied
 Local/regional lymph node/lung/brain/liver30 (60.0%)/15 (30.0%)/3 (6.0%)/1 (2.0%)/1 (2.0%)
Change in expression of ER in recurrent tumor
 Negative conversion/no change/positive conversion3 (6.0%)/46 (92.0%)/1 (2.0%)
Change in expression of PgR in recurrent tumor
 Negative conversion/no change/positive conversion15 (30.0%)/35 (70.0%)/0 (0.0%)
Change in expression of HER2 in recurrent tumor
 Negative conversion/no change/positive conversion0 (0.0%)/44 (88.0%)/6 (12.0%)
Change of intrinsic subtype in recurrent tumor
 No/yes45 (90.0%)/5 (10.0%)
 Disease free survival792 (99–3300)
Smoker
 No/yes36 (72.0%)/14 (28.0%)
 Pack-years of smoker30 (1.4–150)
  1. HER2 human epidermal growth factor receptor 2, HRBC hormone receptor-positive breast cancer (ER+ and/or PgR+), HER2BC human epidermal growth factor receptor 2-enriched breast cancer (ER−, PgR−, and HER2+), TNBC triple negative breast cancer (ER−, PgR−, and HER2−)